Usability of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and results interpretation

Emily Gerth-Guyette, Wondimagegn Adissu, Marcelo Brito, Eduardo Garbin, Marcela Macedo, Abhijit Sharma, Santasabuj Das, Marcus V G Lacerda, Dhélio Pereira, Arunansu Talukdar, Daniel Yilma, Sampa Pal, Stephanie Zobrist, Gonzalo J Domingo, Emily Gerth-Guyette, Wondimagegn Adissu, Marcelo Brito, Eduardo Garbin, Marcela Macedo, Abhijit Sharma, Santasabuj Das, Marcus V G Lacerda, Dhélio Pereira, Arunansu Talukdar, Daniel Yilma, Sampa Pal, Stephanie Zobrist, Gonzalo J Domingo

Abstract

Background: Point-of-care glucose-6-phosphate dehydrogenase (G6PD) testing has the potential to make the use of radical treatment for vivax malaria safer and more effective. Widespread use of G6PD tests as part of malaria case management has been limited, in part due to due concerns regarding product usability, user training, and supervision. This study seeks to assess how well end users can understand the Standard™ G6PD Test (SD Biosensor, Suwon, South Korea) workflow, result output, and label after training. This will ultimately help inform test registration and introduction.

Methods: Potential G6PD test users who provide malaria case management at three sites in Brazil, Ethiopia, and India were trained on the use of the SD Biosensor Standard G6PD Test and assessed based on their ability to understand the test workflow and interpret results. The assessment was done through a questionnaire, designed to assess product usability against key technical product specifications and fulfill regulatory evidence requirements. Any participant who obtained 85% or above correct responses to the questionnaire was considered to adequately comprehend how to use and interpret the test.

Results: Forty-five participants, including malaria microscopists, laboratory staff, nurses, and community health workers took part in the study. Seventy-eight percent of all participants in the study (35/45) obtained passing scores on the assessment with minimal training. Responses to the multiple-choice questions indicate that most participants understood well the test intended use, safety claims, and warnings. The greatest source of error regarding the test was around the correct operating temperature. Most test results were also read and interpreted correctly, with the haemoglobin measurement being a more problematic output to interpret than the G6PD measurement.

Conclusions: These data results show how a standardized tool can be used to assess a user's ability to run a point-of-care diagnostic and interpret results. When applied to the SD Biosensor Standard G6PD Test, this tool demonstrates that a range of users across multiple contexts can use the test and suggests improvements to the test instructions and training that can improve product usability, increase user comprehension, and ultimately contribute to more widespread effective use of point-of-care G6PD tests.

Trial registration: NCT04033640.

Keywords: G6PD deficiency; Label comprehension study; Malaria diagnosis; Point-of-care diagnostics; Usability; User proficiency; User training.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Representation of the SD Biosensor STANDARD G6PD Test and key features on the screen. G6PD: glucose-6-phosphate dehydrogenase; g/dL: grams per decilitre; T-Hb: total haemoglobin
Fig. 2
Fig. 2
SD Biosensor STANDARD G6PD Test components. Training materials developed by PATH
Fig. 3
Fig. 3
SD Biosensor STANDARD G6PD Test procedure. Training materials developed by PATH
Fig. 4
Fig. 4
Study approach summary

References

    1. Kosack CS, Page A-L, Klatser PR. A guide to aid the selection of diagnostic tests. Bull World Health Organ. 2017;95:639–645. doi: 10.2471/BLT.16.187468.
    1. Mori M, Ravinetto R, Jacobs J. Quality of medical devices and in vitro diagnostics in resource-limited settings. Trop Med Int Health. 2011;16:1439–1449. doi: 10.1111/j.1365-3156.2011.02852.x.
    1. Murray CK, Gasser RA, Magill AJ, Miller RS. Update on rapid diagnostic testing for malaria. Clin Microbiol Rev. 2008;21:97–110. doi: 10.1128/CMR.00035-07.
    1. Boyce MR, O’Meara WP. Use of malaria RDTs in various health contexts across sub-Saharan Africa: a systematic review. BMC Public Health. 2017;17:470. doi: 10.1186/s12889-017-4398-1.
    1. Wilson ML. Laboratory diagnosis of malaria: conventional and rapid diagnostic methods. Arch Pathol Lab Med. 2013;137:805–811. doi: 10.5858/arpa.2011-0602-RA.
    1. Baird JK, Valecha N, Duparc S, White NJ, Price RN. Diagnosis and treatment of Plasmodium vivax malaria. Am J Trop Med Hyg. 2016;95(6 Suppl):35–51. doi: 10.4269/ajtmh.16-0171.
    1. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64–74. doi: 10.1016/S0140-6736(08)60073-2.
    1. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood. 2020;136:1225–1240. doi: 10.1182/blood.2019000944.
    1. Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14:103–139. doi: 10.1182/blood.V14.2.103.103.
    1. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339. doi: 10.1371/journal.pmed.1001339.
    1. WHO. Guidelines for the treatment of malaria. 3rd Edn. Geneva, World Health Organization. Accessed November 18, 2019.
    1. Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J. 2015;14:377. doi: 10.1186/s12936-015-0896-8.
    1. Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine G6PD testing prior to treatment with primaquine. Malar J. 2017;16:329. doi: 10.1186/s12936-017-1981-y.
    1. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12:e0006230. doi: 10.1371/journal.pntd.0006230.
    1. Ley B, Satyagraha AW, Rahmat H, et al. Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. PLoS Med. 2019;16:e1002992. doi: 10.1371/journal.pmed.1002992.
    1. Anderle A, Bancone G, Domingo GJ, Gerth-Guyette E, Pal S, Satyagraha AW. Point-of-care testing for G6PD deficiency: opportunities for screening. Int J Neonatal Screen. 2018;4:34. doi: 10.3390/ijns4040034.
    1. Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient. Am J Trop Med Hyg. 2019;100:213–221. doi: 10.4269/ajtmh.18-0612.
    1. Alam MS, Kibria MG, Jahan N, Thriemer K, Richards JS, Domingo GJ, et al. Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS ONE. 2018;13:e0206331. doi: 10.1371/journal.pone.0206331.
    1. Chu CS, Bancone G, Kelley M, Advani N, Domingo GJ, Cutiongo-de la Paz EM, et al. Optimizing G6PD testing for Plasmodium vivax case management: why sex, counseling, and community engagement matter. Wellcome Open Res. 2020;5:21.
    1. Chu CS, Freedman DO. Tafenoquine and G6PD: a primer for clinicians. J Travel Med. 2019;26:taz023.
    1. Commons RJ, McCarthy JS, Price RN. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Med J Aust. 2020;212:152–3.e1. doi: 10.5694/mja2.50474.
    1. Kitchakarn S, Lek D, Thol S, Hok C, Saejeng A, Huy R, et al. Implementation of G6PD testing and primaquine for P. vivax radical cure: operational perspectives from Thailand and Cambodia. WHO South East Asia J Public Health. 2017;6:60–8.
    1. Jacobs J, Barbé B, Gillet P, Aidoo M, Serra-Casas E, Van Erps J, et al. Harmonization of malaria rapid diagnostic tests: best practices in labelling including instructions for use. Malar J. 2014;13:505. doi: 10.1186/1475-2875-13-505.
    1. Kapp N, Methazia J, Eckersberger E, Griffin R, Bessenaar T. Label comprehension of a combined mifepristone and misoprostol for medical abortion: a pilot study in South Africa. Contraception. 2020;101:46–52. doi: 10.1016/j.contraception.2019.09.009.
    1. WHO . Technical Specifications Series for submission to WHO prequalification – diagnostic assessment: in vitro diagnostics medical devices to identify Glucose-6-phosphate dehydrogenase (G6PD) activity. Geneva: World Health Organization; 2016.
    1. US Food and Drug Administration. Guidance for Industry: Label Comprehension Studies for Nonprescription Drug Products. Published online 2010.
    1. Tseroni M, Baka A, Kapizioni C, et al. Prevention of malaria resurgence in Greece through the association of mass drug administration (MDA) to immigrants from malaria-endemic regions and standard control measures. PLoS Negl Trop Dis. 2015;9:e0004215. doi: 10.1371/journal.pntd.0004215.
    1. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929–938. doi: 10.1016/S0140-6736(19)31285-1.
    1. G6PD Operational Research Community of Practice. Accessed December 3, 2020.

Source: PubMed

3
Suscribir